(Q68461439)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

title

Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

main subject

phase II clinical trial

1 reference

C Rose

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

T E Lad

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

L J Kilton

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

J Schor

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

S T Rosen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

A H Rossof

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

R R Blough

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

C M Johnson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

publication date

1 February 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

24 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

page(s)

97-99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00216932

24 September 2019

exact match

0 references

cites work

Phase II trial of esorubicin in patients with advanced non-small cell lung cancer

1 reference

12 December 2020

Antitumor activity in mice of 4'-deoxydoxorubicin in comparison with doxorubicin

1 reference

12 December 2020

Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer

1 reference

12 December 2020

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer

1 reference

12 December 2020

New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00216932

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2160920%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

1 reference